Navigation Links
Evaluating a new way to open clogged arteries

CAMBRIDGE, MA -- Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments has drawbacks, including the risk of side effects.

A new study from MIT analyzes the potential usefulness of a new treatment that combines the benefits of angioplasty balloons and drug-releasing stents, but may pose fewer risks. With this new approach, a balloon is inflated in the artery for only a brief period, during which it releases a drug that prevents cells from accumulating and clogging the arteries over time.

While approved for limited use in Europe, these drug-coated balloons are still in development in the United States and have not received FDA approval. The MIT study, which models the behavior of the balloons, should help scientists optimize their performance and aid regulators in evaluating their effectiveness and safety.

"Until now, people who evaluate such technology could not distinguish hype from promise," says Elazer Edelman, the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology and senior author of the paper describing the study, which appeared online recently in the journal Circulation.

Lead author of the paper is Vijaya Kolachalama, a former MIT postdoc who is now a principal member of the technical staff at the Charles Stark Draper Laboratory.

Evolution of technology

Until the late 1970s, the standard treatment for patients with blocked arteries near the heart was bypass surgery. Doctors then turned to the much less invasive process of reopening arteries with angioplasty balloons. Angioplasty quickly became the standard treatment for narrowed arteries, but it is not always a long-term solution because the arteries can eventually collapse again.

To prevent that, scientists developed stents metal, cage-like structures that can hold an artery open indefinitely. However, these stents have problems of their own: When implanted, they provoke an immune response that can cause cells to accumulate near the stent and clog the artery again.

In 2003, the FDA approved the first drug-eluting stent for use in the United States, which releases drugs that prevent cells from clumping in the arteries. Drug-eluting stents are now the primary choice for treating blocked arteries, but they also have side effects: The drugs can cause blood to clot over time, which has led to death in some patients. Patients who receive these stents now need to take other medications, such as aspirin and Plavix, to counteract blood clotting.

Edelman's lab is investigating a possible alternative to the current treatments: drug-coated balloons. "We're trying to understand how and when this therapy could work and identify the conditions in which it may not," Kolachalama says. "It has its merits; it has some disadvantages."

Modeling drug release

The drug-coated balloons are delivered by a catheter and inflated at the narrowed artery for about 30 seconds, sometimes longer. During that time, the balloon coating, containing a drug such as Zotarolimus, is released from the balloon. The properties of the coating allow the drug to be absorbed in the body's tissues. Once the drug is released, the balloon is removed.

In their new study, Kolachalama, Edelman and colleagues set out to rigorously characterize the properties of the drug-coated balloons. After performing experiments in tissue grown in the lab and in pigs, they developed a computer model that explains the dynamics of drug release and distribution. They found that factors such as the size of the balloon, the duration of delivery time, and the composition of the drug coating all influence how long the drug stays at the injury site and how effectively it clears the arteries.

One significant finding is that when the drug is released, some of it sticks to the lining of the blood vessels. Over time, that drug is slowly released back into the tissue, which explains why the drug's effects last much longer than the initial 30-second release period.

"This is the first time we can explain the reasons why drug-coated balloons can work," Kolachalama says. "The study also offers areas where people can consider thinking about optimizing drug transfer and delivery."

In future studies, Edelman, Kolachalama and colleagues plan to further examine how blood flow affects drug delivery. They also plan to study a variety of different drugs and drug coating compositions, as well as how the balloons behave in different types of arteries.


Contact: Sarah McDonnell
Massachusetts Institute of Technology

Related biology news :

1. Reading, writing, arithmetic, and aerobics -- Evaluating the new R in academic performance
2. Evaluating evolutionary rates could shed light into functions of uncharacterized genes
3. New tools for evaluating quality of life for cats, dogs with heart disease
4. Mummy CT scans show preindustrial hunter gatherers had clogged arteries
5. Body fat hardens arteries after middle age
6. Stenting blocked bowel arteries saves lives
7. Softening arteries, protecting the heart
8. New study reveals that every single junk food meal damages your arteries
9. Heart study suggests city center pollution doubles risk of calcium build-up in arteries
10. Fat outside of arteries may influence onset of coronary artery disease
Post Your Comments:
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/29/2015)... , Sept. 29, 2015 News ... productivity while also saving energy , Minimized design ... Low Power Active Mode and embedded Fujitsu PalmSecure authentication ... Fujitsu today shows that good things come ... refreshed models to its enterprise desktop and mobile portfolio. ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... PARK, N.J. and SAN DIEGO ... (BASF) and Mast Therapeutics, Inc. have agreed to collaborate ...  Currently, excipient-grade poloxamer 188 NF, marketed by BASF under ... used in a variety of pharmaceutical and biological applications, ... Poloxamer 188 is the starting material for Mast,s lead ...
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... a non-binding Letter of Intent (LOI) with MediTemp Ltd. (MediTemp) ... a proprietary cooling technology designed to improve sperm quality in ... United States and three million men in ... 44 diagnosed as infertile.  For 42% of those men, the ...
(Date:10/13/2015)... ... , ... Proove Biosciences, a commercial and research leader ... Keck Medicine of the University of Southern California (USC) Pain Center to ... Research Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one ...
(Date:10/12/2015)... ... October 12, 2015 , ... Spirax Sarco, the leader in products ... CSM-C 600 compact clean steam generator . This unit is a skid ... of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 generator can produce up ...
Breaking Biology Technology: